Ghim Jong-Lyul, Phuong Nguyen Thi Thu, Kim Min Jung, Kim Eun-Ji, Song Geun Seog, Ahn Sangzin, Shin Jae-Gook, Kim Eun-Young
Department of Pharmacology and Clinical Pharmacology, PharmacoGenomics Research Center, Inje University College of Medicine, Busan, Republic of Korea.
Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine, Busan, Republic of Korea.
Drug Des Devel Ther. 2019 May 13;13:1623-1632. doi: 10.2147/DDDT.S193254. eCollection 2019.
The aims of this study was to investigate the mutual pharmacokinetic interactions between steady-state atorvastatin and metformin and the effect of food on the fixed-dose combined (FDC) tablet of atorvastatin and metformin extended release (XR). Study 1, an open-labeled, fixed sequence, multiple-dose pharmacokinetic drug-drug interaction study, was divided into 2 parts. Atorvastatin (40 mg) or metformin (1,000 mg) XR tablets were administered once daily via mono- or co-therapy for 7 days. Plasma levels of atorvastatin and 2-OH-atorvastatin, were quantitatively determined for 36 h in part A (n=50) while metformin plasma concentration was measured up to 24 h in part B (n=16) after the last dosing. Study 2, a randomized, open-labeled, single-dose, two-treatment, two-period, two-sequence crossover study, involved 27 healthy subjects to investigate the impact of food intake on the pharmacokinetics of a combined atorvastatin/metformin XR 20/500 mg (CJ-30056 20/500 mg) tablet. After multiple doses of mono- or co-therapy of atorvastatin (40 mg) and metformin (1,000 mg) XR, the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) for the peak plasma concentration at steady state (C) and area under the plasma concentration-time curve during the dosing interval at steady state (AUC) were 1.07 (0.94-1.22) and 1.05 (0.99-1.10) for atorvastatin, 1.06 (0.96-1.16) and 1.16 (1.10-1.21) for 2-OH-atorvastatin, and 1.00 (0.86-1.18) and 0.99 (0.87-1.13) for metformin, respectively. Food delayed time to reach maximum concentration (t), decreased atorvastatin C by 32% with a GMR (90% CI) of 0.68 (0.59-0.78), and increased metformin AUC by 56% with a GMR (90% CI) of 1.56 (1.43-1.69). No clinically relevant pharmacokinetic interaction was seen when atorvastatin was co-administered with metformin. Food appeared to change the absorption of atorvastatin and metformin from an FDC formulation. These alterations were in accordance with those described with the single reference drugs when ingested with food.
本研究的目的是调查稳态阿托伐他汀与二甲双胍之间的相互药代动力学相互作用,以及食物对阿托伐他汀和二甲双胍缓释(XR)固定剂量复方(FDC)片剂的影响。研究1是一项开放标签、固定顺序、多剂量药代动力学药物 - 药物相互作用研究,分为2部分。阿托伐他汀(40 mg)或二甲双胍(1000 mg)XR片剂通过单药治疗或联合治疗每日给药1次,持续7天。在A部分(n = 50)中,在最后一次给药后36小时定量测定阿托伐他汀和2 - 羟基阿托伐他汀的血浆水平,而在B部分(n = 16)中,测定二甲双胍血浆浓度直至24小时。研究2是一项随机、开放标签、单剂量、双治疗、两周期、两序列交叉研究,纳入27名健康受试者,以研究食物摄入对阿托伐他汀/二甲双胍XR 20/500 mg(CJ - 30056 20/500 mg)复方片剂药代动力学的影响。在多次给予阿托伐他汀(40 mg)和二甲双胍(1000 mg)XR单药治疗或联合治疗后,稳态时血浆峰浓度(C)和稳态给药间隔期间血浆浓度 - 时间曲线下面积(AUC)的几何平均比值(GMR)的90%置信区间(CI),阿托伐他汀分别为1.07(0.94 - 1.22)和1.05(0.99 - 1.10),2 - 羟基阿托伐他汀分别为1.06(0.96 - 1.16)和1.16(1.10 - 1.21),二甲双胍分别为1.00(0.86 - 1.18)和0.99(0.87 - 1.13)。食物延迟了达到最大浓度的时间(t),使阿托伐他汀C降低32%,GMR(90% CI)为0.68(0.59 - 0.78),并使二甲双胍AUC增加56%,GMR(90% CI)为1.56(1.43 - 1.69)。当阿托伐他汀与二甲双胍联合给药时,未观察到临床相关的药代动力学相互作用。食物似乎改变了FDC制剂中阿托伐他汀和二甲双胍的吸收。这些改变与单种参比药物与食物一起摄入时所描述的情况一致。